Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a New York City-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company's portfolio includes two development programs utilizing TARA-002, an investigational cell therapy. TARA-002 is based on OK-432, a broad immunopotentiator originally approved by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell therapy is currently approved in Japan and Taiwan for lymphatic malformations (LMs) and multiple oncologic indications. Protara Therapeutics has worldwide rights to TARA-002, excluding Japan and Taiwan, and is exploring its use in oncology and rare disease indications. TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil® in Japan by Chugai Pharmaceutical Co., Ltd.). The company is currently developing TARA-002 for non-muscle invasive bladder cancer (NMIBC) and LMs. Protara Therapeutics is also developing IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, which includes both nutrition and fluids. Neither TARA-002 nor IV Choline Chloride have been approved by the FDA or other comparable regulatory authorities for any indications. The company has not generated any revenues from product sales to date.